Alloy Therapeutics Raises $40M Series E to Scale AI-Driven Biotech Infrastructure
Alloy Therapeutics announced a $40 million Series E funding round, reaching a valuation of approximately $1 billion as it expands beyond antibody discovery into a full-stack biotech infrastructure company. The company will use the funding to strengthen its core discovery platforms, expand preclinical and clinical development services, and further build its AI and data-driven capabilities that connect the drug development lifecycle. With more than 200 partners and over 100 therapeutic programs, Alloy is positioning itself as a central platform that combines AI, real-world data, and lab execution to accelerate and streamline drug development.
Alloy Therapeutics Raises $40M Series E to Scale AI-Driven Biotech Infrastructure